IP Library › Granted Patent US 7,732,451
Granted Patent B2
US 7,732,451 · App. 11/036,282 · Granted Jun 8, 2010

Naphthalene-containing melanocortin receptor-specific small molecule

Assignee: Palatin Technologies, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,732,451
App. No.
11/036,282
Granted
Jun 8, 2010
Kind
B2
Abstract

A method of modulating energy homeostasis in a mammal without eliciting a sexual response by administration of a therapeutically effective amount of a pharmaceutical composition including a melanocortin receptor compound of the formula: where R 1 is a bond or a linker unit including from one to six backbone atoms and an unsubstituted naphthalene group, and L, R 2 , R 3 and R x are as defined in the specification.

Claims (40)

1. A method of decreasing food intake and/or decreasing body weight in a mammal without eliciting a sexual response, comprising administration to a mammal in need thereof of a therapeutically effective amount of a pharmaceutical composition comprising a melanocortin receptor compound of the formula:

wherein:

L is a conformationally restricted ring system consisting of a single non-aromatic heterocyclic ring system, with the single ring comprising 6 atoms;

R 1 is a linker unit comprising from one to six backbone atoms selected from the group consisting of carbon (C), oxygen (O) and nitrogen (N) and an unsubstituted naphthalene group;

R 2 is —(CH 2 ) 4 NH 2 , —(CH 2 ) 3 NHC(NH 2 )═NH, —(CH 2 ) 3 NHCOCH 3 , —(CH 2 ) 3 NHCOOCH 3 , —(CH 2 ) 2 NHC(NH 2 )═NH, —(CH 2 ) 2 NHCONH 2 , —(CH 2 ) 4 NHCOH, —(CH 2 ) 4 NHCOCH 3 , —(CH 2 ) 3 NHCONHCH 3 , —(CH 2 ) 3 NHSO 2 NH 2 , —(CH 2 ) 3 NHSO 2 CH 3, —(CH 2 ) 3 NH 2 , —(CH 2 ) 3 NH(C═NH)NHMe, —(CH 2 ) 3 NH(C═NH)NHEt, —(CH 2 ) 3 NH(C═NH)NHPr, —(CH 2 ) 3 NH(C═NH)NHPr-i, —(CH 2 ) 3 NH(C═NH)NH 2 , —(CH 2 ) 4 NHCONH 2 , —(CH 2 ) 4 NH(C═NH)NH 2 ,

R 3 comprises a linker unit and at least one carbocyclic aromatic ring; and

R x comprises from zero to three additional pendant groups;

or an enantiomer, stereoisomer or diastereoisomer thereof, or a pharmaceutically acceptable salt thereof;

and a pharmaceutically acceptable carrier.

2. The method of claim 1 wherein R 1 is

wherein:

R 4 is H or ═O;

R 5 is (CH 2 ) y , (CH 2 ) y —O, O or NH, where y is 0 to 4; and

R 6 is naphthalene selected from the group consisting of:

where any available carbon atom of naphthalene forms a bond with R 5 , if provided, or the adjacent carbon atom with which R 4 forms a bond if R 5 is not provided.

3. The method of claim 2 wherein R 6 is 2-naphthalene.

4. The method of claim 1 wherein the L ring system comprises at least one nitrogen, and R 3 forms a bond with the at least one nitrogen.

5. The method of claim 4 wherein R 3 is an L- or D-isomer of Phe, Phe(4-F), Phe(4-Br), Phe(4-CF 3 ), Phe(4-Cl), Phe(3-Cl), Phe(2-Cl), Phe(2,4-diCl), Phe(2,4-diF), Phe(3,4-diCl), Phe(5-Cl), Phe(2-Cl,4-Me), Phe(2-Me,4-Cl), Phe(2-F,4-Cl), Phe(4-I), Phe(2,4-diMe), Phe(2-Cl,4-CF 3 ), Phe(3,4-diF), Phe(4-I), Phe(3,4-di-OMe), Phe(4-Me), Phe(4-OMe), Phe(4-NC), or Phe(4-NO 2 ).

6. The method of claim 4 wherein R 3 an L- or D-isomer of Phe, Phe(4-F), Phe(4-Br), Phe(4-CF 3 ), Phe(4-Cl), Phe(3-Cl), Phe(2-Cl), Phe(2,4-diCl), Phe(2,4-diF), Phe(3,4-diCl), Phe(5-Cl), Phe(2-Cl,4-Me), Phe(2-Me,4-Cl), Phe(2-F,4-Cl), Phe(4-I), Phe(2,4-diMe), Phe(2-Cl,4-CF 3 ), Phe(3,4-diF), Phe(4-I), Phe(3,4-di-OMe), Phe(4-Me), Phe(4-OMe), Phe(4-NC), or Phe(4-NO 2 ) and an amine capping group.

7. The method of claim 6 wherein the amine capping group is methyl, dimethyl, ethyl, propyl, isopropyl, butyl, isobutyl, pentyl, hexyl, allyl, cyclopropane methyl, hexanoyl, heptanoyl, acetyl, propionoyl, butanoyl, phenylacetyl, cyclohexylacetyl, naphthylacetyl, cinnamoyl, phenyl, benzyl, benzoyl, 12-Ado, 7′-amino heptanoyl, 6-Ahx, Amc or 8-Aoc.

8. The method of claim 1 wherein each R x is independently hydrogen, a C 1 to C 6 aliphatic linear or branched chain, or a bond or a linker unit comprising from one to nine backbone atoms selected from the group consisting of carbon, sulfur, oxygen and nitrogen and a group comprising at least one aromatic carbocyclic ring.

9. The method of claim 1 wherein L is:

wherein

X is independently (CH 2 ) n , CH, NH, N, O, C═O, C═S, S, S═O or SO 2 , the index value n is 0, 1, 2 or 3, and

R x is independently hydrogen, a C 1 to C 6 aliphatic linear or branched chain, or a bond or a linker unit comprising from one to nine backbone atoms selected from the group consisting of carbon, sulfur, oxygen and nitrogen and a group comprising at least one aromatic carbocyclic ring.

10. A method of claim 1 , wherein the melanocortin receptor compound of the formula:

wherein:

R 2 is —(CH 2 ) 4 NH 2 , —(CH 2 ) 3 NHC(NH 2 )═NH, —(CH 2 ) 3 NHCOCH 3 , —(CH 2 ) 3 NHCOOCH 3 , —(CH 2 ) 2 NHC(NH 2 )═NH, —(CH 2 ) 2 NHCONH 2 , —(CH 2 ) 4 NHCOH, —(CH 2 ) 4 NHCOCH 3 , —(CH 2 ) 3 NHCONHCH 3 , —(CH 2 ) 3 NHSO 2 NH 2 , —(CH 2 ) 3 NHSO 2 CH 3, —(CH 2 ) 3 NH 2 , —(CH 2 ) 3 NH(C═NH)NHMe, —(CH 2 ) 3 NH(C═NH)NHLt, —(CH 2 ) 3 NH(C═NH)NHPr, —(CH 2 ) 3 NH(C═NH)NHPr-i, —(CH 2 ) 3 NH(C═NH)NH 2 , —(CH 2 ) 4 NHCONH 2 , —(CH 2 ) 4 NH(C═NH)NH 2 ,

R 3 comprises a linker unit and at least one carbocyclic aromatic ring;

R 4 is H or ═O;

R 5 is (CH 2 ) y , (CH 2 ) y —O, O or NH, where y is 0 to 4; and

R 6 is naphthalene selected from the group consisting of:

where any available carbon atom of naphthalene forms a bond with R 5 , if provided, or the adjacent carbon atom with which R 4 forms a bond if R 5 is not provided;

X is CH 2 , C═O, C═S, S, S═O or SO 2 ;

or an enantiomer, stereoisomer or diastereoisomer thereof, or a pharmaceutically acceptable salt thereof.

11. The method of claim 10 wherein R 6 is 2-naphthalene.

12. The method of claim 10 wherein R 3 is a D-isomer of Phe, Phe(4-F), Phe(4-Br), Phe(4-CF 3 ), Phe(4-Cl), Phe(3-Cl), Phe(2-Cl), Phe(2,4-diCl), Phe(2,4-diF), Phe(3,4-diCl), Phe(5-Cl), Phe(2-Cl,4-Me), Phe(2-Me,4-Cl), Phe(2-F,4-Cl), Phe(4-I), Phe(2,4-diMe), Phe(2-Cl,4-CF 3 ), Phe(3,4-diF), Phe(4-I), Phe(3,4-di-OMe), Phe(4-Me), Phe(4-OMe), Phe(4-NC), or Phe(4-NO 2 ).

13. The method of claim 10 wherein R 3 a D-isomer of Phe, Phe(4-F), Phe(4-Br), Phe(4-CF 3 ), Phe(4-Cl), Phe(3-Cl), Phe(2-Cl), Phe(2,4-diCl), Phe(2,4-diF), Phe(3,4-diCl), Phe(5-Cl), Phe(2-Cl,4-Me), Phe(2-Me,4-Cl), Phe(2-F,4-Cl), Phe(4-I), Phe(2,4-diMe), Phe(2-Cl,4-CF 3 ), Phe(3,4-diF), Phe(4-I), Phe(3,4-di-OMe), Phe(4-Me), Phe(4-OMe), Phe(4-NC), or Phe(4-NO 2 ) and an amine capping group.

14. The method of claim 13 wherein the amine capping group is methyl, dimethyl, ethyl, propyl, isopropyl, butyl, isobutyl, pentyl, hexyl, allyl, cyclopropane methyl, hexanoyl, heptanoyl, acetyl, propionoyl, butanoyl, phenylacetyl, cyclohexylacetyl, naphthylacetyl, cinnamoyl, phenyl, benzyl, benzoyl, 12-Ado, 7′-amino heptanoyl, 6-Ahx, Amc or 8-Aoc.

15. The method of clam 1 wherein the mammal is suffering from obesity.

Assignments (3)
TERMINATION OF CONFIRMATORY PATENT LICENSES Recorded Dec 23, 2009
From: PALATIN TECHNOLOGIES INC.
To: ASTRAZENECA AB
Reel/Frame 023699/0161 →
LICENSE Recorded Apr 2, 2009
From: PALATIN TECHNOLOGIES, INC.
To: ASTRAZENECA AB
Reel/Frame 022482/0408 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 15, 2005
From: SHARMA, SHUBH D.; SHADIACK, ANNETTE M.; SHI, YI-QUN; WU, ZHIJUN; RAJPUROHIT, RAMESH; BURRIS, KEVIN D.; PURMA, PAPIREDDY
To: PALATIN TECHNOLOGIES, INC.
Reel/Frame 016269/0478 →
Continuity (14)
Continuation In Part 1083751900 · Apr 30, 2004
Continuation In Part 1076207900 · Jan 21, 2004
Continuation In Part 1076188900 · Jan 21, 2004
Continuation In Part PCTUS022557400 · Aug 12, 2002
Continuation In Part PCTUS022557400 · Aug 12, 2002
Provisional Application 6053660600 · Jan 14, 2004
Provisional Application 6054639300 · Feb 19, 2004
Provisional Application 6055974100 · Apr 5, 2004
Provisional Application 6056373900 · Apr 19, 2004
Provisional Application 6047449700 · May 30, 2003
Provisional Application 6044113900 · Jan 17, 2003
Provisional Application 6031140400 · Jan 17, 2003
Provisional Application 6046744200 · May 1, 2003
Related Publication 20050130988A1 · Jun 16, 2005